Comment réduire rapidement la destruction des produits sanguins labiles à l’échelle d’un établissement de santé ? L’expérience du centre hospitalier de la Côte Basque

Bauduer, Frédéric; Recanzone, Hervé; Harcaut, Nicolas; Hoquet, P.M.; Larricq, Dominique

doi:10.1016/j.tracli.2019.03.003

Cited by 1 publication

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors attributed the reduced wastage rates to improvements in distribution policies (e.g., allowing hospitals to return unused units prior to expiration) and healthcare worker training on the appropriate use of blood. Similar findings have been reported in single‐center publications, which have noted that further reductions in platelet waste could be achieved through the expansion of platelet storage to 7‐days 32 …”

Section: Resultssupporting

confidence: 88%

See 1 more Smart Citation

Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7‐day storage

Pitman

Payrat²,

Park

et al. 2023

Transfusion

View full text Add to dashboard Cite

Background: France converted to universal pathogen reduced (PR; amotosalen/UVA) platelets in 2017 and extended platelet component (PC) shelf-life from 5-to 7-days in 2018 and 2019. Annual national hemovigilance (HV) reports characterized longitudinal PC utilization and safety over 11 years, including several years prior to PR adoption as the national standard of care. Methods: Data were extracted from published annual HV reports. Apheresis and pooled buffy coat [BC] PC use was compared. Transfusion reactions (TRs) were stratified by type, severity, and causality. Trends were assessed for three periods: Baseline (2010-14; $7% PR), Period 1 ([P1] 2015-17; 8%-21% PR), and Period 2 ([P2] 2018-20; 100% PR). Results: PC use increased by 19.1% between 2010 and 2020. Pooled BC PCproduction increased from 38.8% to 68.2% of total PCs. Annual changes in PCs issued averaged 2.4% per year at baseline, À0.02% (P1) and 2.8% (P2). The increase in P2 coincided with a reduction in the target platelet dose and extension to 7-day storage. Allergic reactions, alloimmunization, febrile nonhemolytic TRs, immunologic incompatibility, and ineffective transfusions accounted for >90% of TRs. Overall, TR incidence per 100,000 PCs issued declined from 527.9 (2010) to 345.7 (2020). Severe TR rates declined 34.8% between P1-P2. Forty-six transfusion-transmitted bacterial infections (TTBI)

show abstract

Section: Resultssupporting

confidence: 88%

“…Similar findings have been reported in single-center publications, which have noted that further reductions in platelet waste could be achieved through the expansion of platelet storage to 7-days. 32…”

Section: Platelet Production and Units Issuedmentioning

confidence: 99%